In lung cancer, it has been shown to act as a tumor suppressor (Okudela et al., 2009); conversely, it is upregulated in glioblastoma and HER2-positive breast cancer (Lucci et al., 2010; Messina et al., 2011). This evidence concerns the gene ERBB2 and breast carcinoma.